Skip to main content
. Author manuscript; available in PMC: 2016 Jun 1.
Published in final edited form as: Cancer. 2015 Feb 11;121(11):1800–1808. doi: 10.1002/cncr.29290

Figure 2.

Figure 2

Overall survival curves (A: all stages, n=4,635; C: stage I/II, n=2,475; E: stage III/IV, n=1,832) and lymphoma-related survival curves (B: all stages, n=4,066; D: stage I/II, n=2,188; F: stage III/IV, n=1,584) by age category among patients initially receiving R-CHOP. OS=overall survival; LRS=lymphoma-related survival; R-CHOP=rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone.